Janssen to Advance Health Worldwide

Beerse, Belgium – 22 January 2014 – Janssen announced the formation of Janssen Global Public Health (Janssen GPH), unifying the company’s commitment to research, develop, and deliver transformational medicines to address the world’s greatest unmet public health needs and to sustainably advance health for people all over the world.

“To solve today’s greatest public health challenges, it’s essential that we emphasize the needs of the developing world in equal measure to those of the developed world,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman of Janssen. “With this new group, we’ve adopted a more focused approach to further develop and introduce our most promising medicines, and with other like-minded organisations, we look forward to advancing a sustainable platform that will make a significant impact on the lives of people around the world.”

Janssen GPH is one part of Janssen’s and Johnson & Johnson’s shared response to the world’s global public health challenges. Other organisations and operating companies within the company have launched and continue to support comprehensive efforts toward strengthening the health of communities, improving maternal and child health, and preventing the spread of infectious and preventable diseases worldwide through vaccination. Janssen GPH will partner with other organisations within the Company as appropriate to advance global public health goals.

Janssen GPH will be responsible for clinical and product development and creating and implementing innovative new access strategies for a growing portfolio of pharmaceuticals, diagnostics, and services for diseases significantly impacting resource-limited countries and emerging markets.

Diseases Janssen GPH will focus on include multi-drug resistant tuberculosis, elephantiasis and river blindness - two difficult-to-treat parasitic diseases-, intestinal worms and HIV.

Please read the full press release here.